Liver Tumors: New Technologies and New Managements 2013

Key Topics

• Diagnostic modalities and best approach For cholangiocarcinoma, hepatocellular carcinoma, neuroendocrine tumors and colorectal tumors
• Subtleties of underlying conditions and comorbidities among patients with hepatocellular carcinoma
• Strategies for the use of individual and combination therapies
• The full range of treatment options currently available for treating cholangiocarcinomas, hepatocellular carcinomas, neuroendocrine tumors and colorectal tumors
• Mechanisms of disease and the relevance to the future development of molecular-tailored diagnostic and treatment modalities for cholangiocarcinomas, hepatocellular carcinomas, neuroendocrine tumors and colorectal tumors
• Importance and utility of the multidisciplinary approach to the treatment of cholangiocarcinomas, hepatocellular carcinomas, neuroendocrine tumors and colorectal tumors
• How combining treatment options for colorectal tumors can achieve successes that transcend any single modality
• New standards for determining the indications and contraindications for surgical intervention of colorectal cancers, cholangiocarcinomas and neuroendocrine tumors
• Rationale and success of new, more aggressive treatment strategies for neuroendocrine tumors

Who should Attend

Surgical oncologists, gastroenterologists, surgeons and other healthcare professionals who treat patients with primary or metastatic liver tumors and primary care physicians.